US67080M1036 - Common Stock
NURIX THERAPEUTICS INC
NASDAQ:NRIX (5/17/2024, 10:35:26 AM)
15.79
+0.39 (+2.53%)
Nurix Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in San Francisco, California and currently employs 297 full-time employees. The company went IPO on 2020-07-24. The firm is focused on the discovery, development and commercialization of small molecule and cell therapies based on the modulation of cellular protein levels as a treatment approach for cancer and other diseases. The company DELigase is an integrated discovery platform to identify and advance drug candidates targeting E3 ligases. Its drug candidates include NX-2127, NX-5948, NX-1607 and DeTIL-0255. Its lead drug candidate, NX-2127, is an orally available Bruton’s tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies. Its NX-5948 is an orally bioavailable BTK degrader for the treatment of relapsed or refractory B- cell malignancies and potentially autoimmune diseases. Its NX-1607 is an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. DeTIL-0255 is a drug-enhanced tumor-infiltrating lymphocyte (TIL) therapy.
NURIX THERAPEUTICS INC
1700 Owens St Ste 205
San Francisco CALIFORNIA 94158
P: 14156605320
CEO: Arthur T. Sands
Employees: 297
Website: https://www.nurixtx.com/
Overall response rate of 70% observed in 10 evaluable heavily pretreated CLL patients Data showcase deepening clinical responses with longer time on...
SAN FRANCISCO, May 07, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted...
SAN FRANCISCO, April 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the closing of its underwritten public offering...
SAN FRANCISCO, April 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the pricing of its upsized underwritten public...
SAN FRANCISCO, April 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted...
Here you can normally see the latest stock twits on NRIX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: